# Gilead Sciences clinical trials: 696 (November 2026)

Updated November 19, 2026.

ClinicalTrials.gov lists 696 trials with Gilead Sciences as lead sponsor, 30 of them recruiting or not yet recruiting, as read on November 19, 2026.

## The full list

Clinical trials led by Gilead Sciences: 696 rows for $34.80, every trial on ClinicalTrials.gov as read on November 19, 2026. Columns: NCT ID, Title, Sponsor, Sponsor class, Phase, Status, Conditions, Condition groups (MeSH), Interventions, Start date, First posted, Last update posted, Enrollment, Location countries, Read on, Source. The new rows each week by email, about 1 row a month: $19 a month. Pay by card with no account. Prices exclude VAT. CSV and Excel files with the columns this page does not show (sponsor class, condition groups (MeSH), interventions, start date, last update posted and location countries), which open on your screen as soon as the payment clears and come by email. The rows on this page are a sample.

Buy: https://specstream.ai/data/clinical-trials/company/gilead-sciences

SpecStream is the live web data engine for teams and agents. It reads ClinicalTrials.gov each morning, and this page is that reading. Ask for the sponsors, conditions, phases or places you follow and each new or changed trial arrives in your sheet, CRM, Slack or agent with the sponsor, phase, status and sites.

- Trials: 696
- Recruiting or not yet: 30
- Read on: November 19, 2026

## Trials

The 25 newest of 696, each linked to its ClinicalTrials.gov record. The full list holds every one.

| First posted | NCT ID | Title | Sponsor | Phase | Status | Conditions | Enrollment | Source |
| --- | --- | --- | --- | --- | --- | --- | --- | --- |
| November 3, 2026 | NCT07912996 | Study to Compare GS-1179 Versus Valacyclovir in HSV-2 Seropositive Participants With Recurrent Genital Herpes | Gilead Sciences | Phase 2 | Not yet recruiting | HSV-2 Infection | 300 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07912996) |
| November 2, 2026 | NCT07908446 | Study of BIC/LEN FDC Versus Stable Baseline Regimens in Virologically Suppressed People With HIV | Gilead Sciences | Phase 4 | Not yet recruiting | HIV-1 Infection | 400 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07908446) |
| September 25, 2026 | NCT07841990 | Substudy-01: A Study of Long-Acting HIV-1 Treatments Taken by Mouth in People With HIV-1 With Undetectable Virus Levels | Gilead Sciences | Phase 2 | Recruiting | HIV-1 Infection | 125 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841990) |
| September 25, 2026 | NCT07841977 | Study of Seladelpar and Cilofexor in Participants With Primary Biliary Cholangitis | Gilead Sciences | Phase 2 | Recruiting | Primary Biliary Cholangitis | 132 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07841977) |
| September 8, 2026 | NCT07806773 | Study of TUB-040 in Participants With Unresectable or Metastatic Nonsquamous Non-small Cell Lung Cancer | Gilead Sciences | Phase 2 | Not yet recruiting | NSCLC, Non Small Cell Lung Cancer | 80 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07806773) |
| August 4, 2026 | NCT07743541 | Study of TUB-040 in Patients With Recurrent or Progressive Uterine Cancer After Chemotherapy and Immune Therapy | Gilead Sciences | Phase 1/2 | Not yet recruiting | Uterine Endometrial Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07743541) |
| July 30, 2026 | NCT07736937 | Study of TUB-040 Given With Standard Ovarian Cancer Drugs in Patients With Fast-growing Ovarian Cancer | Gilead Sciences | Phase 1/2 | Recruiting | Ovarian Cancer | 72 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07736937) |
| July 22, 2026 | NCT07719491 | Study of GS-0415 and How It Works in People With HIV | Gilead Sciences | Phase 1 | Recruiting | HIV -1 Infection | 112 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07719491) |
| July 16, 2026 | NCT07708727 | Study of an Injectable Regimen of GS-3242 With Lenacapavir Compared to Biktarvy in People New to HIV-1 Treatment | Gilead Sciences | Phase 2/3 | Recruiting | HIV-1-infection | 700 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07708727) |
| July 15, 2026 | NCT07703878 | A Study to Evaluate the Safety and Antitumor Activity of GS-1206 in Adults With Solid Tumors | Gilead Sciences | Phase 1 | Recruiting | Solid Tumor | 302 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07703878) |
| July 6, 2026 | NCT07683000 | Study of Lenacapavir, Teropavimab, and Zinlirvimab in Virologically Suppressed Adults With HIV-1 on Stable Oral Treatment Regimens | Gilead Sciences | Phase 3 | Recruiting | HIV-1-infection | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07683000) |
| July 6, 2026 | NCT07682961 | Study of Lenacapavir, Teropavimab, and Zinlirvimab Versus Cabotegravir and Rilpivirine in Virologically Suppressed Adults With HIV-1 on... | Gilead Sciences | Phase 3 | Recruiting | HIV Infections | 590 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07682961) |
| June 12, 2026 | NCT07645287 | A Study of GS-3242 in Combination With Lenacapavir Versus Biktarvy in Virologically Suppressed People With HIV-1 | Gilead Sciences | Phase 2 | Recruiting | HIV-1-infection | 175 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07645287) |
| May 22, 2026 | NCT07601243 | Study of GS-2426 in Participants With Advanced Solid Tumors | Gilead Sciences | Phase 1 | Recruiting | Advanced Solid Tumors | 174 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07601243) |
| April 23, 2026 | NCT07546812 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or Chemotherapy in Adults With Metastatic Gastric, Gastroesophageal Junction... | Gilead Sciences | Phase 2 | Active not recruiting | HER2-negative, Gastroesophageal Junction, Esophageal Adenocarcinoma, Gastric Adenocarcinoma | 120 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07546812) |
| April 14, 2026 | NCT07527858 | Study of Denikitug (GS-1811) Given Alone or With Nivolumab or With Chemotherapy in Adults With Advanced Colorectal Cancer | Gilead Sciences | Phase 2 | Recruiting | Advanced Microsatellite Stable Colorectal Cancer | 170 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07527858) |
| March 16, 2026 | NCT07473778 | Implementation Study of Lenacapavir Pre-exposure Prophylaxis for HIV Prevention | Gilead Sciences | Observational | Recruiting | HIV Infections | 3,000 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07473778) |
| August 17, 2025 | NCT07128303 | Study of GS-5319 Given Alone or in Combination in Adults With Solid Tumors | Gilead Sciences | Phase 1 | Recruiting | Advanced Solid Tumor | 476 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07128303) |
| August 11, 2025 | NCT07115368 | Study of GS-1219 in Participants With HIV-1 | Gilead Sciences | Phase 1 | Terminated | HIV-1-infection | 4 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07115368) |
| July 31, 2025 | NCT07096193 | Study of GS-4321 in Healthy Participants and Participants With Chronic Hepatitis Delta Virus | Gilead Sciences | Phase 1/2 | Recruiting | Chronic Hepatitis Delta | 200 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07096193) |
| July 9, 2025 | NCT07055451 | Study of Bictegravir/Emtricitabine/Tenofovir Alafenamide in Newborns Exposed to HIV | Gilead Sciences | Phase 1 | Active not recruiting | HIV-1-infection | 16 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07055451) |
| July 2, 2025 | NCT07047716 | Study of Lenacapavir as a Once-Yearly Injection for HIV Pre-exposure Prophylaxis (PrEP) | Gilead Sciences | Phase 3 | Active not recruiting | HIV Pre-exposure Prophylaxis | 339 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07047716) |
| June 3, 2025 | NCT07001319 | Study of GS-3242 in Participants With HIV-1; Substudy-05 | Gilead Sciences | Phase 1 | Completed | HIV-1-infection | 27 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT07001319) |
| April 15, 2025 | NCT06926920 | A Study of Sacituzumab Govitecan Given at an Alternative Dose and Schedule in Participants With Advanced Triple-Negative Breast Cancer | Gilead Sciences | Phase 1/2 | Recruiting | Triple Negative Breast Cancer | 100 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06926920) |
| March 30, 2025 | NCT06902519 | Study of GS-0151 in Participants With Rheumatoid Arthritis | Gilead Sciences | Phase 1 | Active not recruiting | Rheumatoid Arthritis | 65 | [clinicaltrials.gov](https://clinicaltrials.gov/study/NCT06902519) |

## By phase

| Phase | Trials |
| --- | --- |
| Phase 1 | 131 |
| Phase 1/2 | 40 |
| Phase 2 | 221 |
| Phase 2/3 | 19 |
| Phase 3 | 194 |
| Phase 4 | 37 |
| Not applicable | 19 |
| Observational | 35 |

## By status

| Status | Trials |
| --- | --- |
| Completed | 468 |
| Terminated | 123 |
| Active not recruiting | 43 |
| Recruiting | 26 |
| Withdrawn | 16 |
| Approved for marketing | 8 |
| Unknown | 7 |
| Not yet recruiting | 4 |
| No longer available | 1 |

## Conditions

| Condition group | Trials |
| --- | --- |
| Hepatitis C | 108 |
| HIV Infections | 75 |
| Acquired Immunodeficiency Syndrome | 35 |
| Hepatitis C, Chronic | 34 |
| Leukemia, Lymphocytic, Chronic, B-Cell | 34 |
| Hepatitis B, Chronic | 34 |
| Hepatitis | 25 |
| Hepatitis B | 22 |
| Cystic Fibrosis | 22 |
| Lymphoma, Non-Hodgkin | 21 |
| Fibrosis | 18 |
| Non-alcoholic Fatty Liver Disease | 16 |
| Liver Diseases | 15 |
| Lymphoma, Follicular | 14 |
| Virus Diseases | 14 |
| Diabetes Mellitus, Type 2 | 12 |
| Arthritis, Rheumatoid | 12 |
| Triple Negative Breast Neoplasms | 11 |
| Colorectal Neoplasms | 11 |
| Pseudomonas Infections | 11 |
| Liver Cirrhosis, Biliary | 10 |
| COVID-19 | 10 |
| Lymphoma, B-Cell, Marginal Zone | 10 |
| Coronary Artery Disease | 10 |
| Breast Neoplasms | 9 |

## Where the register publishes

- [ClinicalTrials.gov](https://clinicaltrials.gov/)
- [ClinicalTrials.gov API](https://clinicaltrials.gov/data-api/api)

Source: [ClinicalTrials.gov API v2 (U.S. National Library of Medicine)](https://clinicaltrials.gov/data-api/api). U.S. government data; ClinicalTrials.gov terms of use. Studies are as their sponsors registered them on ClinicalTrials.gov, read through its API. Recruiting means the record's overall status is recruiting or not yet recruiting. Condition groups are the MeSH terms ClinicalTrials.gov assigns; a condition page also counts the narrower terms that name it, as the register's own search does (triple negative breast neoplasms are breast neoplasms). Sites are shown as organizations only; no investigator or contact is read or shown.

Free to quote with credit and a link. Copying in bulk needs a [data licence](https://specstream.ai/data/licence).

## Business lists in the United States

- [Printing equipment suppliers in the United States](https://specstream.ai/data/businesses/printing-equipment-suppliers/united-states)
- [Moroccan restaurants in the United States](https://specstream.ai/data/businesses/moroccan-restaurants/united-states)
- [Insulation contractors in the United States](https://specstream.ai/data/businesses/insulation-contractors/united-states)
- [Flour mills in the United States](https://specstream.ai/data/businesses/flour-mills/united-states)
- [Dental laboratories in the United States](https://specstream.ai/data/businesses/dental-laboratories/united-states)
- [Building contractors in the United States](https://specstream.ai/data/businesses/building-contractors/united-states)
